KeDANCT06090422
Ketamine for Combined Depression and Alcohol Use Disorder
StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
At risk: Primary completion moved 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Jul 1, 2027 to Jul 1, 2028 Show 4 more changesShow less
- Eligibility criteria expanded, about 4 words
- Study sites: 1 to 2
- Secondary endpoints: details revised at 1 of 5 entries
- Collaborators: 1 to 2
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Jan 1, 2025 to Jan 20, 2025
- Notable Start date: Jan 1, 2024 to Jan 1, 2025
- Primary endpoints: 5 to 1
- Secondary endpoints: 3 to 5
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Depression
Timeframe: Within 3 days after final treatment session
Secondary (5)
Alcohol craving tonic
Alcohol craving phasic
Depression response/remission
Relapse risk
Time until relapse
Arms and interventions
Intervention groupExperimental
Ketamine, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks)
Control groupActive comparator
Midazolam, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks)
Drugs: Ketamine Hydrochloride, Midazolam Hydrochloride
Sites
2 sites in 1 country